LEXINGTON, Mass.–(BUSINESS WIRE)—- $AGEN #Armenia–Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases who have previously received ava
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks

